Martin Post

USPTO Granted Patents = 9 (Patent Applications = 4)

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 2.6

ph-index = 3

Forward Citations = 22(Granted Patents)

Company Filing History:

4 out of 52

Mount Sinai Hospital Corporation

patents

2 out of 165

The Hospital for Sick Children

The Hosptial for Sick Children

patent

6. 1 out of 832,912

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2025

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12312598 - Method of generating hemangioblasts (2025-05-27),

2. 12146161 - Mammalian alveolar macrophages derived from pluripotent cells (2024-11-19),

3. 11001806 - Mammalian alveolar macrophages derived from pluripotent cells (2021-05-11),

4. 8889132 - Antibodies against human HIF-1α (2014-11-18),

5. 8007769 - Method for diagnosing an increased risk of preeclampsia by measuring the level of HIF-α (2011-08-30),

6. 7754495 - Methods for early diagnosing of an increased risk of preeclampsia (2010-07-13),

7. 7445940 - Method for diagnosing increased risk of preeclampsia (2008-11-04),

8. 6863880 - Methods to diagnose a required regulation of trophoblast invasion (2005-03-08),

9. 6376199 - Methods to diagnose a required regulation of trophoblast invasion (2002-04-23),

Title: The Innovative Contributions of Martin Post

Introduction

Martin Post is a distinguished inventor based in Toronto, Canada. He has made significant contributions to the field of stem cell research, holding a total of nine patents. His work focuses on the differentiation of pluripotent stem cells into specialized cell types, which has important implications for regenerative medicine.

Latest Patents

Among his latest patents is a method of generating hemangioblasts. This method involves differentiating pluripotent stem cells in a serum-free medium that includes bone morphogenetic protein 4 (BMP4), vascular endothelial growth factor (VEGF), and stem cell factor (SCF). This innovative approach allows for the generation of hemangioblasts or hemangioblast-containing embryoid bodies. Additionally, he has developed a method for generating alveolar-like macrophages from hemangioblasts. This process includes culturing hemangioblasts in a hematopoietic-inducing medium and subsequently in an alveolar macrophage-inducing medium.

Career Highlights

Martin Post has worked with notable institutions such as Mount Sinai Hospital Corporation and The Hospital for Sick Children. His research has contributed to advancements in understanding stem cell differentiation and its applications in medicine.

Collaborations

Some of his notable coworkers include Isabella Caniggia and Stephen Lye. Their collaborative efforts have furthered the research in stem cell applications and regenerative therapies.

Conclusion

Martin Post's innovative work in stem cell research and his numerous patents highlight his significant contributions to the field. His methods for generating specialized cell types are paving the way for future advancements in regenerative medicine.

This text is generated by artificial intelligence and may not be accurate.